Regulations.gov document
[TAB 40] Merisko-Liversidge, et al. Formulation and antitumor activity evaluation of…
Supporting & Related Material · FDA-2015-P-0732 · posted Mar 10, 2015
Key facts
| Document ID | FDA-2015-P-0732-0043 |
|---|---|
| Title | [TAB 40] Merisko-Liversidge, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res, 1996;13:272-278. Citizen Petition From Celgene (Arnold and Porter) |
| Document type | Supporting & Related Material |
| Subtype | Publication |
| Agency | FDA |
| Docket | FDA-2015-P-0732 |
| Posted | Mar 10, 2015 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: